Galecto Inc (GLTO) Opciones

GALT MENTIONED IN THIS ARTICLE.

https://www.zerohedge.com/news/2024-10-15/what-merck-doesnt-want-you-know-about-keytruda

Please watch this and comment your opinion

GLTO under $15

BIXT:

https://www.globenewswire.com/news-release/2024/06/27/2905450/0/en/Bioxytran-s-Advisor-Releases-Book-on-Hyperbaric-Oxygenation-Related-to-Stroke-Alzheimer-s-Patients.html

Share this.


https://medicaldialogues.in/medicine/news/galectin-3-promising-biomarker-for-predicting-long-covid-among-patients-of-covid-19-study-129158

Share this news with everyone, you know

https://www.insiderfinancial.com/post/playing-the-bird-flu-trade-cvac-bixt-nnvc-govx-dyai-nvax

Todays emerging growth conference
CEO DAVID PLATT $BIXT
BioxyTran.

https://emerginggrowth.com/emerging-growth-conference-70/

https://www.nasdaq.com/press-release/6-stocks-positioned-to-soar-as-investors-focus-on-mash-2024-04-22

https://www.zerohedge.com/news/2023-12-12/disease-x-resistance-futile

glto on the move

Galecto Announces Plans to Explore Strategic Alternatives
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. Galecto has made the determination to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value.

As part of this evaluation process, Galecto will explore potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination, divestiture of its assets, technologies or capabilities, or other transaction. There can be no assurance that its exploration will result in Galecto pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms, if at all.

In connection with the evaluation of strategic alternatives, Galecto plans to implement a restructuring plan that includes reducing its workforce by approximately 29 people, or approximately 70% of its existing headcount.

Galecto has not set a timetable for completion of the evaluation process and does not intend to disclose further developments or guidance on the status of its programs unless and until it is determined that further disclosure is appropriate or necessary.

As of June 30, 2023, Galecto’s cash, cash equivalents and investments balance was $52.1 million.

Please share this!

https://x.com/MikeSheikh2/status/1704381059411169763?s=20

Look at this Reprint. Share this !

https://www.preprints.org/manuscript/202309.0077/v1

https://www.zerohedge.com/news/2023-09-12/mask-mandates-unpopular-due-existence-next-gen-antivirals-pipeline

Did anyone catch this today ?

H.C. Wainwright 25th Annual Global Investment Conference

Date: Monday, September 11, 2023
Time: 7:00 am ET
Location: New York City, NY

When is this company going to start doing more to publicize itself. They could be more up front and active with the share holders.

Added a few down here

Damn shame
Sold quite a while ago at a profit

$GLTO (.80) -65% Galecto to discontinue development of lung disease treatment
Reuters
Tue, August 15, 2023 at 7:35 AM EDT

Aug 15 (Reuters) - Galecto Inc said on Tuesday it will dicontinue development of its lung disease treatment after it failed to meet its primary goal in a mid-stage study. (Reporting by Sriparna Roy in Bengaluru; Editing by Arun Koyyur)

https://finance.yahoo.com/news/galecto-discontinue-development-lung-disease-113556937.html

GLTO now ;No 11; on the Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

GLTO new 52/week high
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

Monksdream, I hope we see considerable more traffic on this board soon. Earnings coming out 7/28/2023.

GLTO No 3 on the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc